Alentis Therapeutics
Drug Discovery & Development
1 open role Drug Discovery & Development Allschwil, Switzerland 67 employees $366M raised Est. 2019
OrbiMed
Novo Holdings
Jeito Capital
Frazier Life Sciences
Longitude Capital
Catalio Capital Management
About Alentis Therapeutics
- Alentis Therapeutics is a clinical-stage biotechnology company pioneering first-in-class antibody-drug conjugates (ADCs) and antibodies targeting Claudin-1.
- They are focused on developing innovative treatments for CLDN1+ tumors, cancer, and fibrotic diseases, including advanced liver diseases.
Alentis Therapeutics is listed on Rocketlist with 1 active role. The company is categorized as Drug Discovery & Development in BioTech. Alentis Therapeutics is at Series D+ stage, with a B2B business model, headquartered in Allschwil, Switzerland. Alentis Therapeutics was founded in 2019 and has 67 employees. Alentis Therapeutics has raised $366M. Active roles are refreshed daily from public hiring sources.